Amgen entered a deal to gain US rights to Servier's oral drug ivabradine, which is approved in the EU as Procoralan, for chronic heart failure and stable angina in patients with elevated heart rates, the companies reported Tuesday. Procoralan was approved in the EU in 2005 for symptomatic treatment of stable angina and in 2012 for chronic heart failure .
Under the collaboration, Amgen will also obtain an exclusive option to develop and commercialise Servier's experimental molecule S38844 for cardiovascular diseases in the US. S38844 is currently in Phase II development for the treatment of heart failure. In addition, the French company will gain rights to commercialise omecamtiv mecarbil in Europe. The cardiac myosin activator omecamtiv mecarbil, which is being developed under an agreement  between Amgen and Cytokinetics, is currently in Phase II development for potential applications in the treatment of heart failure in patients with systolic dysfunction.
The companies noted that Amgen will make a one-time payment of $50 million to Servier in addition to future milestone and royalty payments linked to ivabradine, while financial terms were not revealed for Amgen's option on S38844 and Servier's option for omecamtiv mecarbil. Both drugmakers will be permitted to exercise their respective options through the completion of certain Phase II studies.